Biopharma claims their drug reduces mortality from coronavirus

The Ukrainian pharmaceutical company Biopharma claims that its drug in a complex of pneumonia therapy based on biovenous immunoglobulins allegedly “fourfold – from 23.6% to 6.25%” reduces mortality in the critical course of coronavirus disease. This was reported on Facebook.

President of the company Kostiantyn Efimenko said that 35 patients in the placebo group – eight of them died, in the group with Bioven – 32, two died.

Efimenko clarified that clinical trials, randomized on the basis of nine centers, were conducted on a minimum number of people due to the fact that this is a narrow group with a complex course of the disease, on mechanical ventilation or ECMO.